Search results
Showing 271 to 285 of 1164 results for criteria
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Upadacitinib for treating active ankylosing spondylitis (TA829)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Micropressure therapy for refractory Ménière's disease (HTG285)
Evidence-based recommendations on micropressure therapy for refractory Ménière's disease. This involves inserting a grommet (small tube) through the eardrum into the middle ear and blowing air at low pressure into the inner ear.
View recommendations for HTG285Show all sections
Sections for HTG285
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.